Physician profile
Kelly Stankiewicz
NPI 1598987307
$2,132.28
in general payments reported to CMS, 2019-2025
16 companies · $684 in 2025
The $684 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $79.41 · 2021: $248 · 2022: $91.29 · 2023: $143 · 2024: $421 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $616.59 | 2024-2025 | Daxxify |
| Allergan, INC. | $536.23 | 2019-2022 | |
| Abbvie INC. | $305.87 | 2024-2025 | |
| Prugen, INC. Pharmaceuticals | $151.66 | 2019-2020 | |
| Galderma Laboratories, L.P. | $139.37 | 2019-2025 | |
| Stryker Corporation | $131.37 | 2019 | |
| Arcutis Biotherapeutics, INC. | $50.65 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $32.23 | 2023 | Vtama |
| Pfizer INC. | $28.64 | 2022-2023 | |
| Organon LLC | $20.44 | 2025 | |
| Celgene Corporation | $20.30 | 2019 | |
| Incyte Corporation | $20.28 | 2023 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $20.24 | 2025 | |
| Sun Pharmaceutical Industries INC. | $20.15 | 2025 | |
| Lilly USA, LLC | $19.49 | 2024 | Taltz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.77 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Stankiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.